IL-32θ negatively regulates IL-1β production through its interaction with PKCδ and the inhibition of PU.1 phosphorylation  by Kim, Man Sub et al.
FEBS Letters 588 (2014) 2822–2829journal homepage: www.FEBSLetters .orgIL-32h negatively regulates IL-1b production through its interaction
with PKCd and the inhibition of PU.1 phosphorylationhttp://dx.doi.org/10.1016/j.febslet.2014.06.029
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Abbreviations: PMA, phorbol 12-myristate 13-acetate; PKC, protein kinase c;
LPS, lipopolysaccharide; RACE, 50 Rapid Ampliﬁcation of cDNA Ends; IRF, interferon
regulatory factor; TLR, toll like receptor
⇑ Corresponding author. Fax: +82 2 444 4218.
E-mail address: ydy4218@konkuk.ac.kr (D.-Y. Yoon).Man Sub Kim a, Jeong-Woo Kang a, Dong Hun Lee a, Yesol Bak a, Yun Sun Park a, Yong-Seok Song a,
Sun Young Hama, Deok Kun Oh a, Jintae Hong b, Do-Young Yoon a,⇑
aDepartment of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Neungdong-ro 120, Gwangjin-gu, Seoul 143-701, Republic of Korea
bCollege of Pharmacy, Medical Research Center, Chungbuk National University, 12 Gashin-dong, Heungduk-gu, Cheongju, Chungbuk 361-463, Republic of Korea
a r t i c l e i n f o a b s t r a c tArticle history:
Received 3 March 2014
Revised 20 May 2014
Accepted 4 June 2014
Available online 1 July 2014






THP-1It has been well known that IL-32 exerts pro-inﬂammatory effects on the various inﬂammatory dis-
eases in clinical studies. Here, we conﬁrmed that IL-32h, a new isoform of IL-32, decreased the phor-
bol 12-myristate 13-acetate (PMA)-induced IL-1b expression in THP-1 human myelomonocyte. We
previously reported that the IL-32 isoforms control expressions of other cytokines via novel PKCs.
Likewise, IL-32h interacted with PKCd, and consequently inhibited PKCd-mediated phosphorylation
of PU.1. Moreover, IL-32h attenuated the localization of PU.1 into the IL-1b promoter region. These
ﬁndings reveal that IL-32h reduces PKCd-mediated phosphorylation of PU.1, resulting in attenuation
of IL-1b production.
Structured summary of protein interactions:
IL-32 theta physically interacts with PKC delta by anti tag coimmunoprecipitation (1, 2)
IL-32 theta physically interacts with PKC epsilon by anti tag coimmunoprecipitation (1, 2)
PKC delta physically interact with PU.1 by anti tag coimmunoprecipitation (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction interactions with other molecules. IL-32a interacts with integrin,IL-32 has been shown to be a pro-inﬂammatory cytokine in
immune responses [1–4]. The expression of IL-32 is strongly
related to several human inﬂammatory diseases, including rheu-
matoid arthritis, inﬂammatory bowel disease, chronic rhinosinus-
itis, and pulmonary diseases [4–9], and it has nine isoforms by
mRNA alternative splicing: IL-32a, IL-32b, IL-32c, IL-32d, IL-32e,
IL-32f, IL-32g, IL-32h and IL-32s [10–12]. The major isoforms of
IL-32, such as IL-32a, IL-32b, and IL-32c, have been shown to
enhance inﬂammatory response. However, IL-32b augments the
expression and secretion of the anti-inﬂammatory cytokine IL-10
[13–16]. The mode of mechanism of IL-32 remains unclear,
because its receptor has not been characterized yet and it hardly
secretes outside from the cell. Recently, IL-32 has been found to
play a pivotal role in intracellular signaling through theirpaxillin and focal adhesion kinase 1, which are involved in the
formation of the focal adhesion protein complex [17]. In addition,
IL-32a interacts with protein kinase c (PKC) as an intracellular
mediator, resulted in the modulation of IL-6 production in
IL-32a-expressing myelomonocytes [18].
PKC is a family of protein kinases that are modulated by other
proteins by the phosphorylation of serine and threonine residues
[19]. PKC has been shown to be an intracellular mediator that is
involved in immune signaling through the regulation of cytokines
in human cells such as monocytes as well as in mouse models [20–
22]. PU.1 plays important role in granulocyte–macrophage lineage
commitment as an E26-transforming speciﬁc family transcription
factor [23]. PU.1 inﬂuences the induction of cytokines in human
monocytes and macrophages [24].
We have previously reported that intracellular role of IL-32
isoforms through interaction with PKCs. PKC mediated IL-1b
production is implicated in PU.1 activation in THP-1 human
myelomonocyte upon phorbol 12-myristate 13-acetate (PMA)
stimulation. In this study, we investigated the intracellular media-
tory role of IL-32h, a new isoform of IL-32, in IL-1b production in
PMA activated THP-1 human myelomonocyte. Our results
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production.
2. Materials and methods
2.1. Cell culture and the establishment of stably expressed cell lines
The humanmonocytic THP-1 cell linewas cultured in RPMI 1640
medium (WelGENE, Daegu, Korea) supplemented with 2 mM L-glu-
tamine, 100 units/ml penicillin, 100 lg/ml streptomycin, and 10%
fetal bovine serum (HyClone, Logan, UT). The human embryonic
kidney (HEK) 293 cell line was grown in DMEM medium supple-
mented with 2 mM L-glutamine, 100 units/ml penicillin, 100 lg/
ml streptomycin, and 10% fetal bovine serum. To establish constitu-
tive expression systems of IL-32h, THP-1 cells were transfectedwith
the pcDNA3.1+6 Myc or pcDNA3.1+6 Myc-IL-32h vector using
the Neon™ transfection system (Invitrogen, Carlsbad, CA). G-418
(700 lg/ml)-resistant cells were screened for 3 weeks, and single
cell-expanded clones were obtained by serial dilutions.
2.2. Reagents and antibodies
PMA, lipopolysaccharide (LPS), and poly I:C were purchased
from Sigma (St. Louis, MO). PKC inhibitors (Gö6976, Gö6850, and
rottlerin) were from Calbiochem. Antibodies speciﬁc to FLAG-tag
were from Sigma. Antibodies speciﬁc to myc tag, HA tag, and phos-
pho-Threonine were from Millipore (Millipore, Bedford, MA).
KU32-52, a monoclonal anti-IL-32 antibody, was produced as
previously reported [25].
2.3. Construction of expression vectors and the Luc reporter plasmid
for IL-1b
We have previously cloned IL-32h by 50 Rapid Ampliﬁcation of
cDNA Ends (RACE) in which a new isoform of IL-32 was isolated
from dendritic cells [12]. The 6 Myc tag was inserted into pcDNA
3.1+, and then IL-32h cDNA was subcloned into pcDNA3.1+-6
Myc vector using EcoRI and XhoI. The cDNA of PKC isoforms such
as PKCa, PKCd, PKCh, and PKCe were subcloned into pcDNA3.1+-
5 FLAG vector as previously described [18]. The deletion mutants
of PKCd were synthesized by PCR and their PCR products were also
cloned into pcDNA3.1+-5 FLAG vector using EcoRI and XhoI. PU.1
cDNA was subcloned into pcDNA3.1+HA vector using EcoRI and
XhoI as previously described [26]. The IL-1b promoter region
(126 to +11) was PCR-ampliﬁed from THP-1 genomic DNA. The
primer set was 50-CCACCAATACTCTTTTCCCC-30 (sense) and 50-
CTGGCAGATACCAAACCTCT-30 (antisense). The PCR product was
digested with KpnI and BglII restriction enzymes. The digested
fragment (126 to +11) was ligated into the pGL3-Basic vector.
2.4. PCR analysis for pro-inﬂammatory cytokines and silencing of IL-32
expression by siRNA
The mRNA expression of pro-inﬂammatory cytokines such as IL-
1b, IL-6, IL-8 and the transcription factor PU.1 were detected by RT-
PCR of the total RNA extracted from THP-1 cells expressing the
mock vector or IL-32h after the various experimental treatments.
The pro-inﬂammatory cytokines and PU.1 primers sequences were
as follows: IL-1b, 50-TACATCCTCGACGGCATCTCA-30 (sense) and 50-
CTACATTTGCCGAAGAGCCCT-30 (antisense); IL-6, 50-TACATCCTCGA
CGGCATCTCA-30 (sense) and 50-CTACATTTGCCGAAGAGCCCT-30
(antisense); IL-8, 50-CTTGGCAGCCTTCCTGA TTT-30 (sense) and
50-CTCAGCCCTCTTCAAAAACT-30 (antisense). THP-1/IL-32h cells
were transfected with IL-32 siRNA or scrambled siRNA using the
Neon™ transfection system as previously described [27].2.5. Cytokine production assessed by enzyme-linked immunosorbent
assay
THP-1/mock vector cells and THP-1/IL-32h cells were
treated with several stimulants and inhibitors, such as PMA,
LPS, poly I:C, and rottlerin. After centrifugation, the cultured
media were obtained and the expression levels for IL-1b,
IL-8, and IL6 were detected using their respective ELISA kits
(R&D Systems, Minneapolis, MN) according to the manufac-
turer’s instructions.
2.6. Promoter activity assay for IL-1b
pGL3-IL-1b promoter (1 lg), pRL-null (Renilla, 0.1 lg), PU.1
(1 lg), and PKCd (1 lg) expression vectors were co-transfected into
THP-1 cells with or without the IL-32h expression vector (1 lg)
using the Neon™ transfection system (Invitrogen). Luciferase
assays were performed using the dual-luciferase reporter assay
system (Promega, Madison, WI). THP-1/mock vector cells and
THP-1/IL-32h cells were transfected overnight with pRL-null
(Renilla, 0.1 lg) and the pGL3-IL-1b promoter (1 lg) using the
Neon™ transfection system and then treated with 10 nM of PMA
for 24 h. Luciferase assays were performed using the dual-lucifer-
ase reporter assay system.
2.7. Immunoﬂuorescence
A549 cells were incubated on the cover-slip and co-transfected
with 1 lg of pcDNA3.1+6 Myc-IL-32h, pcDNA3.1+5 FLAG-PKCd.
Then cells were treated with 10 nM of PMA at 30 min and 60 min.
After cover-slip was isolated, cells were ﬁxed and permeabilized
with 4% para-formaldehyde and 0.5% saponin for 10 min. After
washing with PBS, cells were blocked with 1% BSA, and then cells
were incubated with anti-Myc and anti-FLAG antibody (1:200) at
room-temperature for 2 h. After washing with PBS, cells were
stained with anti-mouse antibody conjugated with rhodamine
(1:400) and anti-rabbit antibody conjugated with FITC (1:400)
for 2 h. Nuclei were stained with DAPI (1:2000) for 10 s after
washing with PBS. Images were obtained by using Olympus
BX61-32FDIC upright ﬂuorescence microscope (Olympus, Tokyo,
Japan).
2.8. Immunoblotting and immunoprecipitation
HEK293 cells were co-transfected with pcDNA3.1+6 Myc-IL-
32h, pcDNA3.1+5 FLAG-PKCa, -PKCd, -PKCh, -PKCe, and
pcDNA3.1+HA-PU.1. THP-1 cells were treated with 10 nM of PMA
after pre-treatment with 10 lM of rottlerin. These cells were har-
vested and lysed in a buffer containing 50 mM HEPES (pH 7.5),
150 mM NaCl, 5% glycerol, 20 mM glycerophosphate, 1% Nonidet
P-40, 0.5% Triton X-100, and 1 mM EDTA. Protein concentrations
were determined using a Bio-Rad protein assay kit (Bio-Rad, CA)
and samples were subjected to 12% SDS–polyacrylamide gel elec-
trophoresis (SDS–PAGE) before being transferred to polyvinylidene
diﬂuoride (PVDF) membranes (Millipore, Billerica, MA). The mem-
branes were blocked with 5% non-fat dry milk dissolved in PBST
containing 140 mM NaCl, 27 mM KCl, 10 mM Na2HPO412H2O,
1.8 mM KH2PO4, and 0.05% Tween-20. Western blotting was used
to visualize the adherent proteins usingWestzol plus theWestern
Blot Detection System (iNtRON Biotechnology) and detected using
the EZ-capture MG protein imaging system (ATTO, Tokyo, Japan).
For immunoprecipitation, the cell lysates were mixed with each
1 lg of anti-Myc antibody and anti-FLAG antibody for 1 h and then
pulled down using 40 ll of protein G-agarose beads (KPL, Gaithers-
burg, MD) [18].
Fig. 1. Constitutive expression systems of 6 Myc-tagged IL-32h were established
in THP-1 monocytic cells. The pcDNA3.1+6 Myc tagged-IL-32h was transfected
into THP-1 cells by electroporation and then underwent selection using G-418 for
3 weeks. IL-32h expression levels were conﬁrmed by RT-PCR using IL-32-speciﬁc
primers and Western blot using anti-IL-32 antibody (KU-52) with or without 10 nM
PMA treatment for 24 h.
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THP-1/mock cells and THP-1/IL-32h cells were treated with
PMA for 8 h. ChIP assays were carried out using the ChIP assay
kit (Millipore) according to the manufacturer’s instructions. Brieﬂy,
the cells were ﬁxed with 1% formaldehyde for 10 min at 37 C,
lysed for 10 min using 1 ml of a lysis buffer with proteaseFig. 2. The production of IL-1b was diminished by IL-32h with PMA in dose- and time-
10 nM PMA, 1 lg/ml LPS, and 10 lg/ml poly I:C for 24 h. IL-1b, IL-8, and IL-6 mRNA levels
ELISA (D–F). THP-1/mock vector and THP-1/IL-32h cells were treated with PMA in a tim
levels (G–I) were assessed by RT-PCR and ELISA. THP-1/mock vector cells versus THP-1/I
dose for 24 h and then IL-1b, IL-8, and IL-6 mRNA (C) and protein levels (J–L) were assesse
(n = 3). ⁄P < 0.05. THP-1/mock vector cells versus THP-1/IL-32h cells under PMA treatmeinhibitors, and then sonicated with three pulses for 10 s each. After
sonication, samples were diluted 10-fold in ChIP Dilution Buffer
and centrifuged at 13,000 rpm for 15 min. The supernatants were
mixed with or without the respective anti-PU.1 antibody and
rotated overnight at 4 C. Protein A-agarose/salmon sperm DNA
(50% slurry) was added to each sample, and the pulled-down
DNA fragments were eluted. The eluted DNA was ampliﬁed using
PCR for 35 cycles at an annealing temperature of 58 C. The primer
sequences for the IL-1b promoter were as follows: 50-TTGCATGGT-
GATACATTTGC-30 (sense) and 50-CAGTTTCTCCCTCGCTGTTT-30
(antisense).
2.10. Statistical analysis
Statistical analyses were performed using the one-way analysis
of variance (ANOVA) (P < 0.05) with the Tukey’s HSD test. Experi-
ments were performed with three independent replicates and the
data were expressed as the means ± standard deviations (SD,
n = 3) with the following signiﬁcance level: ⁄P < 0.05.
3. Results
3.1. Construction of THP-1 cell lines stably expressing IL-32h
In this study, we previously cloned IL-32h which is a novel iso-
form of IL-32 [12]. To investigate how IL-32h is involved in thedependent manners. THP-1/mock vector and THP-1/IL-32h cells were treated with
were assessed by RT-PCR (A) and secreted levels of each cytokines were assessed by
e-dependent manner at 10 nM and then IL-1b, IL-8, and IL-6 mRNA (B) and protein
L-32h cells under PMA treatment. Both cells were treated with PMA at the indicated
d by RT-PCR and ELISA. The ELISA data are presented as means ± standard deviations
nt.
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for IL-32h by the transfection of 6 Myc or 6 Myc-tagged IL-
32h in THP-1 myelomonocytic cells that were subcultured for
3 weeks. Then, we could obtain two cell lines, THP-1/mock vector
cells which were used as controls and THP-1/IL-32h cells. As shown
in Fig. 1, the expression levels of intracellular IL-32h mRNA and
protein were increased by PMA treatment in THP-1/IL-32h cells.
3.2. IL-32h negatively regulates PMA-induced IL-1b production
Human myelomonocytes THP-1 cells, participate in the
immune response against various kinds of stimulation. IL-32 iso-
forms have typically been characterized as pro-inﬂammatory
cytokines in the immune system [28,29]. However, IL-32 isoforms
do not always exert pro-inﬂammatory effects. The IL-32b isoform
induces an anti-inﬂammatory cytokine IL-10 [16,27]. To investi-
gate whether IL-32h could modulate the genes related to the
immune response in THP-1 human monocytes, we performed
microarray analysis for PMA-treated THP-1/mock vector cells and
THP-1/IL-32h cells, revealing that IL-1b transcripts were two-folds
decreased in THP-1/IL-32h cells compared with THP-1/mock vector
cells (unpublished data). We ﬁrst conﬁrmed which stimuli can
induce pro-inﬂammatory cytokines and chemokines (Fig. 2A,
D–F). In our system, only PMA could induce proinﬂammatory cyto-
kines in mRNA and protein expressions, not LPS and Poly I:C. IL-32h
decreased IL-1b production, whereas it did not affect IL-6 and IL-8
productions in THP-1/IL-32h cells. We next conﬁrmed a decrease in
IL-1bmRNA (Fig. 2B and C) in a dose and time-dependent manners
in PMA-treated THP-1/IL-32h cells stimulated by PMA treatment.
However, other pro-inﬂammatory cytokines, such as IL-6 and IL-
8, were not decreased. Under the same conditions, the ELISA assay
further conﬁrmed that the secretion levels of IL-1bwere also inhib-
ited in PMA-treated THP-1/IL-32h cells (Fig. 2G–L). The mRNA and
secretion levels of IL-6 and IL-8 were not altered, while IL-6 secre-
tion was slightly increased by PMA treatment in THP-1/IL-32h
cells. When another cell line HL-60 human promyelocytic
leukemia cells, which can produce proinﬂammatory cytokinesFig. 3. IL-32h suppressed IL-1b production through PKC activation. (A and B), 6Myc-tag
treated with 10 nM of PMA for 24 h. The mRNA and secreted protein levels of IL-1bwere
50 nM of IL-32 siRNA using electroporation. After PMA treatment, IL-32h dependent IL
treatment, the PKCd speciﬁc inhibitor rottlerin was used in the pre-treatment of both cel
PCR and ELISA (F), respectively. The ELISA data are presented as mean ± standard deviat
treatment.from PMA stimulation, are transfected with 6 myc-tagged IL-
32h after PMA stimulation, IL-1b production partially decreased
(Fig. 3A and B). We next block IL-32h expression by using IL-32 siR-
NA (Fig. 3C and D). IL-1b expression levels of mRNA and protein are
marginally increased in IL-32h knock-downed cells. These results
indicated that IL-32h has shown inhibitory effect on IL-1b produc-
tion in another leukemia cells, and may contribute to regulate
IL-1b production in intracellular signaling pathways. We further
conﬁrmed the mRNA expression and protein secretion levels of
IL-1b through the pretreatment of rottlerin, a PKCd-speciﬁc inhib-
itor (Fig. 3E and F). Although PMA was used to treat both cell lines,
IL-1b mRNA expression and secretion were inhibited with
pretreatment with rottlerin. These results demonstrated that
PMA-derived IL-1b induction was dependent on PKCd and that
IL-32h was involved in the PKCd-mediated process leading to
IL-1b production.
3.3. IL-32h interacts with PMA-activated PKCd
PMA, as an analog of diacylglycerol, mainly targets classical and
novel PKCs [30]. To verify the correlation between PKC isoforms
and the suppression of IL-1b production by IL-32h, we conducted
co-transfection and co-immunoprecipitation with 6 Myc-tagged
IL-32h and 5 FLAG-tagged PKCs (PKCa, d, h, and e) under PMA
treatment for 3 h. We observed that IL-32h interacted with PMA-
activated novel PKCs (PKCd and PKCe), among other PKC isoforms
(Fig. 4A). Above all, IL-32h was mainly bound to PKCd, and this
interaction was bilaterally conﬁrmed by immunoprecipitation
using anti-6 Myc-antibody and anti-5 FLAG-antibody (Fig. 4B
and C). Moreover, this interaction was blocked by rottlerin, a PKCd
speciﬁc inhibitor, and Gö6850, a non-speciﬁc PKC inhibitor, but not
Gö6976, a classical PKC inhibitor (Fig. 4D). Additionally, to investi-
gate which domain of PKC was involved in interaction with IL-32h,
we separated the PKC into its two domains, regulatory and cata-
lytic domain. Only regulatory domain, but not catalytic domain
of PKCd, interacted with IL-32h (Fig. 4E). Additionally, we further
conﬁrmed co-localization with IL-32h (green) and PKCd (red) afterged IL-32hwas transfected into HL-60 cells for overnight, and then HL-60 cells were
performed by RT-PCR and ELISA. (C and D), THP-1/IL-32h cells were transfected with
-1b inhibitory effect was assessed by RT-PCR and ELISA. In addition, before PMA
l lines. The mRNA and secreted protein levels of the cytokines were assessed by RT-
ion (n = 3). ⁄P < 0.05. THP-1/mock vector cells versus THP-1/IL-32h cells under PMA
Fig. 4. IL-32h interacted with PMA-activated novel PKCs. (A) HEK293 cells were co-transfected with an expression vector of 6 Myc-tagged IL-32h and 5 Flag-tagged PKC
isoforms (PKC-a, d, h, and e). Under PMA treatment for 3 h, interactions between IL-32h and PKC isoforms were conﬁrmed by immunoprecipitation with 1 lg of anti-Myc
antibody. Pulled down PKC isoforms were detected by Western blot analysis using anti-Flag antibody (B and C). The speciﬁc interactions between IL-32h and PKCd were
conﬁrmed by immunoprecipitation using 1 lg of anti-Flag and anti-Myc tagged antibodies after co-transfection with PMA treatment for 3 h (D). The 6 Myc expression
vector tagged with IL-32h and the 5 Flag vector tagged with PKCd were co-transfected with HEK293 cells and were pretreated with the PKCd-speciﬁc inhibitor rottlerin, the
classical PKCs inhibitor G}o6975, and the pan-PKC inhibitor G}o6850 for 1 h before PMA treatment. (E) Each 1 lg of 6 myc-tagged IL-32h and 5 FLAG-tagged PKCd-Full,
PKCd-reg (regulatory domain), and PKCd-cat (catalytic domain) were co-transfected into HEK293 cells. Then, cells treated with PMA for 3 h, and their interactions were
conﬁrmed by immunoprecipitation using 1 lg of anti-myc tagged antibody. (F) A549 cells were transfected with 1 lg of 6 myc-tagged IL-32h and 5 FLAG-tagged PKCd.
Under PMA treatment at indicated time points, IL-32h and PKCd were stained with antibody conjugated with rhodamine (red) and FITC (green), respectively. Nuclear was
stained with DAPI.
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and mitochondria as well as plasma membrane through the regu-
latory domain of PKCd [31], and we previously detected co-locali-
zation with IL-32b and PKCd around nuclear section [32].
Interestingly, after PMA treatment, IL-32h partially permeated
from cytosol into nuclear and also PKCd has concentrated into sev-
eral spots and co-localized with IL-32h all around including
nuclear. These data indicated that PKCd was mainly involved inIL-32h-derived IL-1b suppression through the association of
IL-32h with regulatory domain of PKCd.
3.4. IL-32h inhibits the PU.1 activity through interaction with PKCd
PU.1 has been well known to bind to PKCd and become phos-
phorylated by activated PKCd on its threonine and senrin residues
[33,34]. Thus, we conﬁrmed how IL-32h was involved to the
Fig. 5. IL-32h suppressed the interaction between PKCd and PU.1, resulting in inhibition of phosphorylation of PU.1 through interaction with PKCd. The IL-32h, PU.1, PKCd (A
and B) or PKCe (C) expression vectors co-transfected with HEK293 cells were treated with PMA for 3 h. The interaction of PKCd or PKCewith IL-32h and PU.1 was conﬁrmed by
immunoprecipitation using 1 lg of anti-FLAG or Myc tagged antibody. (D) Each 1 lg of IL-32h, PKCd, and indicated dose of PU.1 expression vector were co-transfected in
HEK293 cells and then cells treated with PMA for 3 h. Their interactions were conﬁrmed by immunoprecipitation using 1 lg of anti-FLAG tagged antibody.
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monocytes. We carried out immunoprecipitation after transfection
of the expression vectors, including 6Myc-IL-32h, 5 FLAG-PKCd,
and PU.1-HA, under PMA stimulation for 3 h. In the absence of
IL-32h, PU.1 was phosphorylated by PKCd after PMA stimulation,
as predicted. However, the phosphorylation of PU.1 through its
interaction with PKCd was inhibited by IL-32h co-transfection
(Fig. 5A). Additionally, when PKCd and PU.1 were pull-downed by
IL-32h with anti-myc antibody, we could not observe the interac-
tion between IL-32h and PU.1 (Fig. 5B). In the case of PKCe that
could be interacted with IL-32h, it does not bind to PU.1 and
neither affects its activity (Fig. 5C). Interestingly, the more PU.1
strongly interacted with PKCd, the weaker the binding between
IL-32h and PKCd (Fig. 5D). These results suggest that IL-32h may
suppress the binding of PKCd to PU.1 and consequently PU.1
phosphorylation.
3.5. IL-32h suppresses DNA binding and transactivation of PU.1
targeting to IL-1b promoter
IL-1b transcription was induced by PU.1 alone or was enhanced
by forming complexes with other transcription factors [35,36]. To
conﬁrm that these results exerted a decisive effect on the DNA
binding ability of the IL-1b promoter region, we established spe-
ciﬁc primers for the IL-1b promoter region (162 to 1) including
the PU.1 consensus sequence to apply ChIP analysis. We conﬁrmed
the DNA binding ability of PU.1 for the target sequence within the
IL-1b promoter region after PMA stimulation for 8 h. As shown in
Fig. 6A, strong binding of PU.1 to the sheared DNA occurred underPMA stimulation in THP-1/mock cells. On the other hand, the
IL-32h-expressing cells exhibited no DNA binding with the PU.1
transcription factor. These results showed that the inhibition of
PU.1 activity by IL-32h inﬂuenced its DNA binding capability in
the IL-1b promoter.
Hence, we established a 126 to +12 base pair region of the
IL-1b promoter region with the pGL3 basic vector to measure the
luciferase activity. After transfection with IL-1b promoter and ren-
illar, we treated with PMA for 24 h in THP-1/mock vector cells and
THP-1/IL-32h cells, then we conducted luciferase assay. In THP-1/
IL-32h cells, luciferase activity regarding IL-1b promoter was not
altered in contrast with THP-1/mock vector cells (Fig. 6B). We next
co-transfected with PU.1-HA, 6 Myc-IL-32h, IL-1b promoter and
renillar as a control and then treated with rottlerin and PMA. After
the luciferase assay, IL-1b transcripts were increased in the
absence of IL-32h under PMA treatment (Fig. 6C), which suggest
that IL-32h negatively regulate the IL-1b transcription.
4. Discussion
IL-32 is a pro-inﬂammatory cytokine expressed within the
lesions of patients with inﬂammatory diseases, and induces other
pro-inﬂammatory cytokines such as IL-1b, IL-8 and TNF-a
[4,5,10,37–39]. However, recent researches regarding IL-32b and
IL-32c showed that IL-32 can involve the anti-inﬂammatory cyto-
kine production through the promotion of IL-10 production [6,16].
These ﬁndings suggest that IL-32 may have both a pro- and anti-
inﬂammatory effect in immune cells. Moreover, IL-32 isoforms
displayed internal cellular activity through their interaction with
Fig. 6. IL-32h inhibited the binding of PU.1 to the IL-1b promoter and its transactivity. (A) A schematic showing the IL-1b promoter and the target sequences of PU.1 binding
tested in the chromatin immunoprecipitation (ChIP) assays. THP-1/mock vector cells and THP-1/IL-32h cells were treated with 10 nM of PMA for 8 h, and then each sample
was ﬁxed with 1% formaldehyde. ChIP assay was carried out with 2 lg of anti-PU.1 antibody, immunoprecipitated with IL-1b promoter by PU.1. (B) THP-1/mock vector cells
and THP-1/IL-32h cells were transfected with 1 lg of IL-1b promoter-Luc and then treated with 10 nM of PMA for 24 h. Each experiment was performed under the dual-
luciferase reporter assay system. Data are presented as mean ± standard deviation (n = 3). ⁄P < 0.05. THP-1/mock vector cells versus THP-1/IL-32h cells under PMA treatment.
(C) THP-1 cells were transfected with 1 lg of IL-1b promoter-Luc, IL-32h and PU.1 expression vector overnight. Cells were pre-treated with 10 lM of rottlerin for 1 h and then
10 nM of PMA treatment for 24 h. Luciferase activity with PU.1 was measured by a dual-luciferase reporter assay system. Data are presented as mean ± standard deviation
(n = 3). ⁄P < 0.05. IL-32h- and PU.1-transfected cells versus only PU.1-transfected cells under PMA treatment.
2828 M.S. Kim et al. / FEBS Letters 588 (2014) 2822–2829other molecules via their binding motifs [17]. Specially, we
previously reported that IL-32 isoforms displayed intracellular
interactions with speciﬁc PKC isoforms, leading to the production
of pro- or anti-inﬂammatory cytokines [18,27].
The novel PKC family is mediated in the immune response
through the production of pro-inﬂammatory cytokines [40–42].
PKCa and PKCd are involved in high glucose induced-immune
responses by inducing the expression of toll like receptor (TLR)
2/4 [43]. Also, PKCd is ubiquitously expressed in lymphoid cells
and enhanced IL-2 secretion [44]. In addition, the lungs of PKCd
knockout mice show attenuated asbestos-induced peribronchiolar
cell proliferation and cytokine production [45].
PKCd promotes the activation of PU.1 by binding to PU.1 and
then inducing the phosphorylation of its transactivator domain
[33]. The electrophoretic mobility shift assay (EMSA) or ChIP assay
revealed that PU.1 has been shown to be involved in the immune
response by binding to multiple target promoters [46,47]. More-
over, PU.1 can be a key regulator of IL-1b transcription because
PU.1 can bind to its consensus sequence within the IL-1b promoter
region [35,48]. In human monocytes, IL-1b transcripts are
regulated by PU.1 alone or PU.1 in addition to other transcriptionfactors such as C/EBPb and interferon regulatory factor (IRF) 4/8
[36,48,49].
In this report, we have shown the intracellular function of
IL-32h which exerts inhibitory effect on PMA-induced IL-1b
production through interaction with PKCd in THP-1 human myelo-
monocytes stably expressing IL-32h. For now, the physiological
studies of IL-32h have to be extended because IL-32h transcript is
expressed in differentiated dendritic cells. However, in this study,
we ﬁrst veriﬁed the IL-32h as a potent intracellular modulator that
attenuates IL-1b production through binding to PKCd, resulting in
the suppression of interaction between PKCd and PU.1.
Consequently, inhibition of PKCd-mediated PU.1 phosphorylation
suppressed IL-1b production. These ﬁndings suggest that IL-32h
can play a role in cytokine production as an intracellular
modulator.
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